Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Wednesday, March 06, 2024Madrigal Pharmaceuticals Inc a clinicalstage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis today announced that
Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars
Wednesday, March 06, 2024Sandoz the global leader in generic and biosimilar medicines today announced that the US Food and Drug Administration approved Wyost and Jubbonti the first and only FDAapproved denosumab biosimilars
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Tuesday, March 05, 2024BridgeBio Pharma Inc and Bayer today announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTRCM in Europe
PepGen Receives UK Regulatory Clearance for Phase 2 Trial of PGN-EDO51 in Duchenne Muscular Dystrophy
Tuesday, March 05, 2024PepGen Inc a clinicalstage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Tuesday, March 05, 2024SpringWorks Therapeutics Inc a commercialstage biopharmaceutical company focused on severe rare diseases and cancer announced today that the Company
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
Monday, March 04, 2024CymaBay Therapeutics Inc a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases today announced that
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
Saturday, March 02, 2024Boston Scientific Corporation today announced it has received US Food and Drug Administration approval for the AGENT DrugCoated Balloon which is indicated to treat coronary instent restenosis
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
Saturday, March 02, 2024Mallinckrodt plc a global specialty pharmaceutical company today announced that the US Food and Drug Administration has approved Mallinckrodts supplemental
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
Friday, March 01, 2024Intercept Pharmaceuticals Inc a biopharmaceutical company and wholly owned subsidiary of Alfasigma SpA focused on the development and commercialization
Microsoft and 1910 Genetics Partner to Build the Infrastructure Layer for Drug Discovery and Development Using AI and High-Performance Computing
Friday, March 01, 2024Genetics the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation
